Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024.

Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET, (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs its shareholders and the market that, at today's Extraordinary General Meeting, the attendance quorum required to deliberate and vote on the items on the agenda has not been reached, and that consequently, the Extraordinary General Meeting was unable to deliberate or vote on the agenda items..

Attendance quorum not met

In accordance with the provisions of the Belgian Companies and Associations Code, an attendance quorum of 50% of the outstanding shares was required to deliberate validly on the agenda items. Despite requests for attendance received, this quorum was not met. The meeting could therefore not proceed to voting.

Convening of a new Extraordinary General Meeting

Consequently, Oxurion will convene an Extraordinary General Meeting on 5 July 2024 to be held on 24 July 2024 at 3pm in Brussels. The agenda remains unchanged and concerns the proposal to consolidate the Company's outstanding shares at a ratio of 1 for 10,000. This second Extraordinary General Meeting will deliberate and decide validly, regardless of the proportion of the capital represented by the shareholders present or represented.

The convening notice and other documents relating to the shareholders' meeting are available on the Oxurion website, along with details of the agenda, location and how shareholders can participate to the meeting.

Additional information

Shareholders are requested to regularly check Oxurion's press releases and website for the latest information on the upcoming Extraordinary General Meeting.

Oxurion would like to thank its shareholders for their understanding and continued support.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is headquartered in Leuven, Belgium. More information is available at .

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Contacts:

Attachments